Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice

详细信息    查看全文

• 作者：Yue-Xiang Li (5) (6)
  Hui Zhao (6)
  Rui-Yuan Cao (6)
  Yong-Qiang Deng (6)
  Jian-Feng Han (6)
  Shun-Ya Zhu (6)
  Jie Ma (6)
  Long Liu (5) (6)
  E-De Qin (5) (6)
  Cheng-Feng Qin (5) (6)
  
  5. Graduate School ; Anhui Medical University ; Hefei ; 230032 ; Anhui ; China
  6. Department of Virology ; State Key Laboratory of Pathogen and Biosecurity ; Beijing Institute of Microbiology and Epidemiology ; Beijing ; China
  
• 关键词：Enterovirus 71 ; Vaccine ; Linear neutralizing epitopes
• 刊名：Virology Journal
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：11
• 期：1
• 全文大小：405 KB
• 参考文献：1. Bible, JM, Pantelidis, P, Chan, PK, Tong, CY (2007) Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol 17: pp. 371-379 38" target="_blank" title="It opens in new window">CrossRef
  2. Cardosa, MJ, Krishnan, S, Tio, PH, Perera, D, Wong, SC (1999) Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet 354: pp. 987-991 36(98)11032-2" target="_blank" title="It opens in new window">CrossRef
  3. Chan, KP, Goh, KT, Chong, CY, Teo, ES, Lau, G, Ling, AE (2003) Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9: pp. 78-85 3201/eid1301.020112" target="_blank" title="It opens in new window">CrossRef
  4. Ho, M, Chen, ER, Hsu, KH, Twu, SJ, Chen, KT, Tsai, SF, Wang, JR, Shih, SR (1999) An epidemic of enterovirus 71 infection in Taiwan: Taiwan enterovirus epidemic working group. N Engl J Med 341: pp. 929-935 33411301" target="_blank" title="It opens in new window">CrossRef
  5. Mao, LX, Wu, B, Bao, WX, Han, FA, Xu, L, Ge, QJ, Yang, J, Yuan, ZH, Miao, CH, Huang, XX, Zhang, C, Xu, H (2010) Epidemiology of hand, foot, and mouth disease and genotype characterization of enterovirus 71 in Jiangsu, China. J Clin Virol 49: pp. 100-104 CrossRef
  6. Wu, Y, Yeo, A, Phoon, MC, Tan, EL, Poh, CL, Quak, SH, Chow, VT (2010) The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 14: pp. e1076-e1081 CrossRef
  7. Hosoya, M, Kawasaki, Y, Sato, M, Honzumi, K, Kato, A, Hiroshima, T, Ishiko, H, Suzuki, H (2006) Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. Pediatr Infect Dis J 25: pp. 691-694 339.c3" target="_blank" title="It opens in new window">CrossRef
  8. Mizuta, K, Abiko, C, Murata, T, Matsuzaki, Y, Itagaki, T, Sanjoh, K, Sakamoto, M, Hongo, S, Murayama, S, Hayasaka, K (2005) Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol 43: pp. 6171-6175 3.12.6171-6175.2005" target="_blank" title="It opens in new window">CrossRef
  9. Herrero, LJ, Lee, CS, Hurrelbrink, RJ, Chua, BH, Chua, KB, McMinn, PC (2003) Molecular epidemiology of enterovirus 71 in peninsular Malaysia, 1997鈥?000. Arch Virol 148: pp. 1369-1385 3-0100-2" target="_blank" title="It opens in new window">CrossRef
  10. Chang, LY (2008) Enterovirus 71 in Taiwan. Pediatr Neonatol 49: pp. 103-112 3-6" target="_blank" title="It opens in new window">CrossRef
  11. Wu, CN, Lin, YC, Fann, C, Liao, NS, Shih, SR, Ho, MS (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: pp. 895-904 385-1" target="_blank" title="It opens in new window">CrossRef
  12. Chen, HF, Chang, MH, Chiang, BL, Jeng, ST (2006) Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24: pp. 2944-2951 CrossRef
  13. Chiu, CH, Chu, C, He, CC, Lin, TY (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8: pp. 1671-1678 CrossRef
  14. Arita, M, Nagata, N, Iwata, N, Ami, Y, Suzaki, Y, Mizuta, K, Iwasaki, T, Sata, T, Wakita, T, Shimizu, H (2007) An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81: pp. 9386-9395 CrossRef
  15. Liu, CC, Lian, WC, Butler, M, Wu, SC (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier vero cell culture. Vaccine 25: pp. 19-24 3" target="_blank" title="It opens in new window">CrossRef
  16. Tung, WS, Bakar, SA, Sekawi, Z, Rosli, R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: pp. 6 CrossRef
  17. Chung, YC, Ho, MS, Wu, JC, Chen, WJ, Huang, JH, Chou, ST, Hu, YC (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: pp. 1855-1862 CrossRef
  18. Ong, KC, Devi, S, Cardosa, MJ, Wong, KT (2010) Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 84: pp. 661-665 CrossRef
  19. Cheng, A, Fung, CP, Liu, CC, Lin, YT, Tsai, HY, Chang, SC, Chou, AH, Chang, JY, Jiang, RH, Hsieh, YC, Su, IJ, Chong, PC, Hsieh, SM (2013) A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31: pp. 2471-2476 3.03.015" target="_blank" title="It opens in new window">CrossRef
  20. Liang, ZL, Mao, QY, Wang, YP, Zhu, FC, Li, JX, Yao, X, Gao, F, Wu, X, Xu, M, Wang, JZ (2013) Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother 9: pp. 1701-1705 CrossRef
  21. Zhu, FC, Meng, FY, Li, JX, Li, XL, Mao, QY, Tao, H, Zhang, YT, Yao, X, Chu, K, Chen, QH, Hu, YM, Wu, X, Liu, P, Zhu, LY, Gao, F, Jin, H, Chen, YJ, Dong, YY, Liang, YC, Shi, NM, Ge, HM, Liu, L, Chen, SG, Ai, X, Zhang, ZY, Ji, YG, Luo, FJ, Chen, XQ, Zhang, Y, Zhu, LW (2013) Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381: pp. 2024-2032 36(13)61049-1" target="_blank" title="It opens in new window">CrossRef
  22. Chan, YF, Sam, IC, AbuBakar, S (2010) Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol 10: pp. 404-412 CrossRef
  23. Xu, J, Qian, Y, Wang, S, Serrano, JM, Li, W, Huang, Z, Lu, S (2010) EV71: an emerging infectious disease vaccine target in the ear East?. Vaccine 28: pp. 3516-3521 3.003" target="_blank" title="It opens in new window">CrossRef
  24. Foo, DG, Alonso, S, Chow, VT, Poh, CL (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: pp. 1299-1306 CrossRef
  25. Li, X, Mao, C, Ma, S, Wang, X, Sun, Z, Yi, Y, Guo, M, Shen, X, Sun, L, Bi, S (2009) Generation of neutralizing monoclonal antibodies against enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 390: pp. 1126-1128 3" target="_blank" title="It opens in new window">CrossRef
  26. Lim, XF, Jia, Q, Khong, WX, Yan, B, Premanand, B, Alonso, S, Chow, VT, Kwang, J (2012) Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One 7: pp. e29751 371/journal.pone.0029751" target="_blank" title="It opens in new window">CrossRef
  27. Liu, CC, Chou, AH, Lien, SP, Lin, HY, Liu, SJ, Chang, JY, Guo, MS, Chow, YH, Yang, WS, Chang, KH, Sia, C, Chong, P (2011) Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 29: pp. 4362-4372 CrossRef
  28. Dudek, NL, Perlmutter, P, Aguilar, MI, Croft, NP, Purcell, AW (2010) Epitope discovery and their use in peptide based vaccines. Curr Pharm Des 16: pp. 3149-3157 38161210793292447" target="_blank" title="It opens in new window">CrossRef
  29. Sette, A, Fikes, J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: pp. 461-470 3)00083-9" target="_blank" title="It opens in new window">CrossRef
  30. Dong, XN, Chen, Y, Wu, Y, Chen, YH (2005) Candidate multi-peptide-vaccine against classical swine fever virus induced potent immunity with serological marker. Vaccine 23: pp. 3630-3633 CrossRef
  31. Ichihashi, T, Yoshida, R, Sugimoto, C, Takada, A, Kajino, K (2011) Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model. PLoS One 6: pp. e24626 371/journal.pone.0024626" target="_blank" title="It opens in new window">CrossRef
  32. Koopman, G, Beenhakker, N, Nieuwenhuis, I, Doxiadis, G, Mooij, P, Drijfhout, JW, Koestler, J, Hanke, T, Fagrouch, Z, Verschoor, EJ, Bontrop, RE, Wagner, R, Bogers, WM, Melief, CJ (2013) DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS 27: pp. 2842-2851 CrossRef
  33. Purcell, AW, McCluskey, J, Rossjohn, J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6: pp. 404-414 38/nrd2224" target="_blank" title="It opens in new window">CrossRef
  34. El-Awady, MK, El Gendy, M, Waked, I, Tabll, AA, El Abd, Y, Bader EI, D, EI Shenawy, R, Allam, A, Abdelhafez, TH, Dawood, RM (2013) Immunogenicity and safety of HCV E1E2 peptide vaccine in chronically HCV-infected patients who did not respond to interferon based therapy. Vaccine.
  35. Liu, JN, Wang, W, Duo, JY, Hao, Y, Ma, CM, Li, WB, Lin, SZ, Gao, XZ, Liu, XL, Xu, YF, Xu, WB, Qin, C, Zhang, LF (2010) Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28: pp. 7444-7451 CrossRef
  36. Tian, X, Su, X, Li, X, Li, H, Li, T, Zhou, Z, Zhong, T, Zhou, R (2012) Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS One 7: pp. e41381 371/journal.pone.0041381" target="_blank" title="It opens in new window">CrossRef
  37. Lin, YC, Wu, CN, Shih, SR, Ho, MS (2002) Characterization of a vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 20: pp. 2485-2493 CrossRef
  38. Sette, A, Keogh, E, Ishioka, G, Sidney, J, Tangri, S, Livingston, B, Mckinney, D, Newman, M, Chesnut, R, Fikes, J (2002) Epitope identification and vaccine design for cancer immunotherapy. Curr Opin Investig Drugs 3: pp. 132-139
  39. Sette, A, Newman, M, Livingston, B, McKinney, D, Sidney, J, Ishioka, G, Tangri, S, Alexander, J, Fikes, J, Chesnut, R (2002) Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens 59: pp. 443-451 34/j.1399-0039.2002.590601.x" target="_blank" title="It opens in new window">CrossRef
  40. Livingston, BD, Newman, M, Crimi, C, McKinney, D, Chesnut, R, Sette, A (2001) Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19: pp. 4652-4660 33-X" target="_blank" title="It opens in new window">CrossRef
  41. Li, HY, Han, JF, Qin, CF, Chen, R (2013) Virus-like particles for enterovirus 71 produced from saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31: pp. 3281-3287 3.05.019" target="_blank" title="It opens in new window">CrossRef
  42. Foo, DG, Alonso, S, Phoon, MC, Ramachandran, NP, Chow, VT, Poh, CL (2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res 125: pp. 61-68 CrossRef
  43. Wang, SM, Chen, IC, Su, LY, Huang, KJ, Lei, HY, Liu, CC (2010) Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin Vaccine Immunol 17: pp. 1517-1523 CrossRef
  44. Han, JF, Cao, RY, Deng, YQ, Tian, X, Jiang, T, Qin, ED, Qin, CF (2011) Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J 8: pp. 106 3-422X-8-106" target="_blank" title="It opens in new window">CrossRef
  45. Chen, IC, Wang, SM, Yu, CK, Liu, CC (2013) Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med Microbiol Immunol 202: pp. 259-265 30-013-0289-y" target="_blank" title="It opens in new window">CrossRef
  46. Cao, RY, Dong, DY, Liu, RJ, Han, JF, Wang, GC, Zhao, H, Li, XF, Deng, YQ, Zhu, SY, Wang, XY, Lin, F, Zhang, FJ, Chen, W, Qin, ED, Qin, CF (2013) Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS One 8: pp. e64024 371/journal.pone.0064024" target="_blank" title="It opens in new window">CrossRef
  47. Foo, DG, Macary, PA, Alonso, S, Poh, CL (2008) Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol 21: pp. 215-224 CrossRef
  48. Cello, J, Strannegard, O, Svennerholm, B (1996) A study of the cellular immune response to enteroviruses in humans: identification of cross-reactive T cell epitopes on the structural proteins of enteroviruses. J Gen Virol 77: pp. 2097-2108 317-77-9-2097" target="_blank" title="It opens in new window">CrossRef
  49. Zhao, H, Li, HY, Han, JF, Deng, YQ, Li, YX, Zhu, SY, He, YL, Qin, ED, Chen, R, Qin, CF (2013) Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against coxsackievirus A16 in mice. Appl Microbiol Biotechnol 97: pp. 10445-10452 3-013-5257-3" target="_blank" title="It opens in new window">CrossRef
  50. Han, JF, Cao, RY, Tian, X, Yu, M, Qin, ED, Qin, CF (2010) Producing infectious enterovirus type 71 in a rapid strategy. Virol J 7: pp. 116 3-422X-7-116" target="_blank" title="It opens in new window">CrossRef
  51. REED, LJ, MUENCH, H (1938) A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27: pp. 493-497
  52. Chen, S, Yu, M, Jiang, T, Deng, Y, Qin, C, Qin, E (2007) Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol 26: pp. 361-367 CrossRef
  53. Cao, RY, Han, JF, Jiang, T, Tian, X, Yu, M, Deng, YQ, Qin, ED, Qin, CF (2011) In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors. J Clin Virol 51: pp. 246-249 CrossRef
  
• 刊物主题：Virology;
• 出版者：BioMed Central
• ISSN：1743-422X

文摘

Background Human Enterovirus 71 (EV71) has emerged as the leading cause of viral encephalitis in children, especially in the Asia-Pacific regions. EV71 vaccine development is of high priority at present, and neutralization antibodies have been documented to play critical roles during in vitro and in vivo protection against EV71 infection. Results In this study, a novel strategy to produce EV71 vaccine candidate based on recombinant multiple tandem linear neutralizing epitopes (mTLNE) was proposed. The three well identified EV71 linear neutralizing epitopes in capsid proteins, VP1-SP55, VP1-SP70 and VP2-SP28, were sequentially linked by a Gly-Ser linker ((G4S)3), and expressed in E.coli in fusion with the Trx and His tag at either terminal. The recombinant protein mTLNE was soluble and could be purified by standard affinity chromatography. Following three dosage of immunization in adult mice, EV71-specific IgG and neutralization antibodies were readily induced by recombinant mTLNE. IgG subtyping demonstrated that lgG1 antibodies dominated the mTLNE-induced humoral immune response. Especially, cytokine profiling in spleen cells from the mTLNE-immunized mice revealed high production of IL-4 and IL-6. Finally, in vivo challenge experiments showed that passive transfer with anti-mTLNE sera conferred full protection against lethal EV71 challenge in neonatal mice. Conclusion Our results demonstrated that this rational designed recombinant mTLNE might have the potential to be further developed as an EV71 vaccine in the future.